Review specialized data on liver cancer treatment and survival presented at the Symposium on Clinical Interventional Oncology 2023.
GI Oncology Now
The leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies
Conference Spotlight
Advertisement
Latest News
This week on GI Friday: An emerging treatment modality for liver tumors, a first-line treatment for mCRC, and more.
Histotripsy is an innovative modality for treating liver tumors that offers several advantages.
The number of arteries treated during transarterial chemoembolization did not affect outcomes in liver cancer patients.
Radiation lobectomy with transarterial embolization of Yttrium-90 is a viable option for hepatocellular carcinoma.
Durvalumab plus tremelimumab significantly improved overall survival in patients with unresectable liver cancer.
A study assessed the efficacy of of several adjuvant therapies for hepatocellular carcinoma.
A study assessed whether the addition of anti-VEGF agent to first-line treatment impacted outcomes in metastatic CRC.
Maintenance with cetuximab monotherapy appeared to improve PFS and OS in patients with metastatic colorectal cancer.
A study assessed the efficacy of a treatment combination in the second-line treatment of metastatic colorectal cancer.
A systematic review reported that immune checkpoint inhibitor therapy shows promising results in metastatic CRC.
Advertisement
Conference Coverage
GI Oncology Now reviews practice-enhancing education from CIO 2023, featuring multidisciplinary specialties in oncology.
